Exozymes (EXOZ) Capital Leases (2025 - 2026)

Exozymes (EXOZ) posted quarterly Capital Leases of $64427.0 for Q4 2025, down 15.91% quarter-over-quarter from $76613.0 in Q3 2025.

Exozymes (EXOZ) Capital Leases (2025 - 2026) Analysis & Trends

Exozymes (EXOZ) has reported Capital Leases for 1 consecutive years, with $64427.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Capital Leases changed N/A year-over-year to $64427.0; the TTM figure through Dec 2025 stood at $64427.0 (changed N/A YoY), while the FY2025 annual figure was $64427.0, changed N/A from the prior year.
Capital Leases eased to $64427.0 in Q4 2025 per EXOZ's latest filing, from $76613.0 in the prior quarter.
Across five years, Capital Leases topped out at $86970.0 in Q2 2025 and bottomed at $64427.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Exozymes	61.53 Mn	61.53 Mn	-

Download Data